Drug Profile
CJ 30039
Alternative Names: CJ-30039Latest Information Update: 30 Jun 2020
Price :
$50
*
At a glance
- Originator CJ Cheiljedang Corp.
- Developer HK inno.N
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 18 Jun 2020 CJ HealthCare is now called HK inno.N
- 16 Jul 2016 No recent reports of development identified for phase-I development in Undefined(In volunteers) in South Korea (PO)
- 30 Jun 2012 CJ Healthcare completes a phase I trial in healthy volunteers in South Korea (NCT01501435)